Taken together, this will enable the personalized stratification of patients with LFS based on the (i) the presence of a P/LP variant in a known cancer gene, (ii) predicted probability of developing cancer using our epimutation cancer risk model, (iii) epimutation cluster analysis, (iv) presence of a P/LP variant in the WNT signaling pathway, and (v) LEF1 methylation (Table 2). This evidence concerns the gene LEF1 and cancer.